...
首页> 外文期刊>Journal of Pharmacopuncture >Antidiabetic Activity of an Ayurvedic Formulation Chaturmukha Rasa: A Mechanism Based Study
【24h】

Antidiabetic Activity of an Ayurvedic Formulation Chaturmukha Rasa: A Mechanism Based Study

机译:阿育吠陀制剂Chaturmukha Rasa的抗糖尿病活性:基于机理的研究。

获取原文
           

摘要

Objectives: The objective of this study was to evaluate antidiabetic activity of Chaturmukha rasa based on streptozotocin induced diabetes model, alpha amylase inhibitory activity, alpha Glucosidase inhibitory activity and inhibition of sucrase. Methods: Chaturmukha rasa was prepared as per Ayurvedic formulary. Antidiabetic activity was measured in experimentally streptozotocin induced rats. The dose was taken as 45 mg/kg, i.p. The antidiabetic activity of Chaturmukha rasa was compared Triphala Kwatha, a marketed formulation. Further In vitro $cute{lpha}$ - Amylase Inhibitory Assay, In vitro salivary amylase Inhibitory Assay, In vitro ${lpha}-Glucosidase$ Inhibitory Assay and In vitro Sucrase Inhibitory Assay was performed with respect to Chaturmukha rasa. The IC50 value was calculated for all the above activity. Results: Streptozotocin with Acarbose showed significant decrease in blood glucose level whereas streptozotocin with Triphala kwatha showed more decrease in blood glucose level than Streptozotocin with Acarbose. The combination of Streptozotocin + Triphala kwatha + Chaturmukha rasa showed a significant decrease in blood glucose level on 21st day. In vitro $cute{lpha}$ - Amylase Inhibitory Assay the Chaturmukha rasa showed IC50 value $495.94{mu}l$ when compared with Acarbose $427.33{mu}l$ , respectively. In the ${lpha}-Glucosidase$ Inhibitory Assay Chaturmukha rasa showed IC50 value $70.93{mu}l$ when compared with Acarbose $102.28{mu}l$ , respectively. In vitro Sucrase Inhibitory Assay Chaturmukha rasa showed IC50 value $415.4{mu}l$ when compared with Acarbose $371.43{mu}l$ , respectively. Conclusion: This study supports that Chaturmukha rasa may inhibit diabetes by inhibition of salivary amylase or alpha Glucosidase or sucrase. This may be the mechanism by which Chaturmukha rasa inhibits diabetes. Further this study supports the usage of Chaturmukha rasa for the management of diabetes.
机译:目的:本研究的目的是基于链脲佐菌素诱导的糖尿病模型,α淀粉酶抑制活性,α葡萄糖苷酶抑制活性和蔗糖酶抑制作用,评估Chaturmukha rasa的抗糖尿病活性。方法:按照印度草药处方制备Chaturmukha rasa。在实验性链脲佐菌素诱导的大鼠中测量了抗糖尿病活性。剂量为45mg / kg,腹膜内。比较了Chaturmukha rasa的抗糖尿病活性Triphala Kwatha,一种市售制剂。关于Chaturmukha rasa,进行了进一步的体外急性{ alpha} $-淀粉酶抑制测定,体外唾液淀粉酶抑制测定,体外$ { alpha}-葡萄糖苷酶抑制测定和体外蔗糖酶抑制测定。计算上述所有活动的IC50值。结果:与阿卡波糖相比,含阿卡波糖的链脲佐菌素的血糖水平明显降低,而与Triphala kwatha相比,链脲佐菌素的血糖水平降低幅度更大。在第21天,链脲佐菌素+ Triphala kwatha + Chaturmukha rasa的组合显示血糖水平显着下降。体外$急性淀粉酶抑制分析与阿卡波糖427.33 {相比,印度ur草显示的IC50值为495.94 {1。在$α-葡糖苷酶抑制试验中,Chaturmukha rasa的IC50值分别为$ 70.93 {μg/ l,而与Acarbose的$ 102.28 $μg/ l相比。体外蔗糖酶抑制分析Chaturmukha rasa与Acarbose 371.43美元相比,IC50值分别为415.4美元/亩。结论:这项研究支持Chaturmukha rasa可能通过抑制唾液淀粉酶或α葡萄糖苷酶或蔗糖酶来抑制糖尿病。这可能是Chaturmukha rasa抑制糖尿病的机制。进一步,该研究支持将Chaturmukha rasa用于糖尿病的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号